About Immucor
Immucor is a company based in United States founded in 1982 was acquired by Werfen in November 2022. Immucor has completed 2 acquisitions, including BioArray Solutions and Organ-i. Immucor operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immucor India Private Limited
- Date of Incorporation 10 Mar, 2012
- Jurisdiction Delhi, India
-
Annual Revenue
$7.4 M (USD)37.88as on Mar 31, 2023
-
Net Profit
$140.78 K (USD)-22.77as on Mar 31, 2023
-
EBITDA
$64.97 K (USD)-92.95as on Mar 31, 2023
-
Latest Funding Round
Not available
-
Investors
TPG
& 2 more
-
Employee Count
Not available
-
Investments & Acquisitions
BioArray Solutions
& 1 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Immucor
Unlock access to complete
Funding Insights of Immucor
Investors in Immucor
Immucor has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, Werfen and The Riverside Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and debt are provided to middle market companies.
|
Locked | Locked | Locked | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Locked | Locked | Locked | |
|
Global leader for In Vitro Diagnostic
|
Locked | Locked | Locked |
Investor details for Immucor
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immucor
Immucor has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include BioArray Solutions and Organ-i.
Investment portfolio details for Immucor
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Molecular diagnostics for organ rejection in transplant patients are developed.
|
Locked | Locked | 2010 | Locked | |
|
Bead-based assays for nucleic acid and protein analysis are developed.
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Immucor
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Immucor
Detailed financials for Immucor
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immucor Comparisons
Peer comparison for Immucor
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immucor
Immucor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Immucor
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immucor
Complete news archive for Immucor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immucor
Immucor was founded in 1982 and raised its 1st funding round 38 years after it was founded.
Immucor is headquartered in United States.
Avi Pelossof is the current CEO of Immucor.
Annual revenue of Immucor is $7.4M as on Mar 31, 2023.
Immucor was founded in 1982 in the United States and operates within the healthcare sector, focusing on diagnostics for transfusion and transplantation. A variety of products is offered, including reagents, capture technologies, automation systems for blood banks, software solutions, and molecular testing tools. These offerings support clinical and laboratory operations in blood management and organ transplantation processes.
Immucor's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Immucor has made 2 acquisitions, including BioArray Solutions, and Organ-i.
Immucor has 3 investors. Key investors include TPG, Werfen, and The Riverside Company.